“…In line with gender‐specific differences in the effect of the ACE‐I/D polymorphism in various conditions and/or diseases, such as blood pressure (among healthy individuals) (Avila‐Vanzzini et al., 2015), hypertension (Higaki et al., 2000; Sipahi, Budak, Şen, Ay1, & Şener, 2006), schizophrenia (Mazaheri, 2015; Nadalin, Buretić‐Tomljanović, Ristić, Jonovska, & Tomljanović, 2015; Nadalin et al., 2012), as well as MS (Lovrečić et al., 2006), and according to observations of gender–gene interaction in risk for nicotine dependence in general population (Beuten, Payne, Ma, & Li, 2006; Beuten et al., 2005; Nedic et al., 2010; Tochigi et al., 2007) and specific diseases (i.e., schizophrenia) (Nadalin, Buretić‐Tomljanović, Rebić, Pleša, & Šendula Jengić, 2016) association analyses between ACE‐I/D polymorphism and smoking habits were performed separately among male and female patients. Furthermore, there is also evidence that estrogen may influence dopaminergic neurotransmission, since it has been observed that estrogen treatment reduces dopamine receptor D2 levels in several rat brain regions (Chavez et al., 2010).…”